Design Therapeutics (DSGN) Assets Average (2021 - 2026)

Design Therapeutics (DSGN) has 6 years of Assets Average data on file, last reported at $228.3 million in Q1 2026.

• For the quarter ending Q1 2026, Assets Average fell 6.72% year-over-year to $228.3 million; the trailing twelve-month figure through Mar 2026 stood at $228.3 million (down 6.72% YoY), and the FY2025 full-year result was $239.1 million, down 11.71% from the prior year.
• Assets Average advanced to $228.3 million in Q1 2026, from $219.0 million in the prior quarter.
• In the past five years, Assets Average ranged from a high of $384.7 million in Q1 2022 to a low of $217.3 million in Q3 2025.
• A 5-year average of $290.5 million and a median of $284.2 million in 2024 frame the typical range for Assets Average.
• Across the five-year window, Assets Average surged 71.59% in 2022 and declined 18.18% in 2025, its largest moves.
• Tracing DSGN's Assets Average over 5 years: stood at $347.9 million in 2022, then fell by 15.26% to $294.8 million in 2023, then declined by 12.86% to $256.9 million in 2024, then decreased by 14.75% to $219.0 million in 2025, then advanced by 4.26% to $228.3 million in 2026.
• Business Quant data shows DSGN's Assets Average at $228.3 million in Q1 2026, $219.0 million in Q4 2025, and $217.3 million in Q3 2025.